...
首页> 外文期刊>Journal of child and adolescent psychopharmacology >Atypical antipsychotic medications to control symptoms of delirium in children and adolescents
【24h】

Atypical antipsychotic medications to control symptoms of delirium in children and adolescents

机译:非典型抗精神病药可控制儿童和青少年的ir妄症状

获取原文
获取原文并翻译 | 示例

摘要

Background: Atypical antipsychotics have been documented to be effective in the management of delirium in adults, but despite considerable need, their use has been less studied in pediatric patients. Objective: A retrospective chart review was done to describe the use of atypical antipsychotics in controlling symptoms of delirium in children and adolescents. Methods: Pharmacy records at Children's Hospital Los Angeles were reviewed to identify patients to whom antipsychotic agents were dispensed over a 24-month period. Psychiatric inpatient consultations during the same 24-month period were reviewed. Patients 1-18 years old diagnosed with delirium given antipsychotics constituted the study population. Delirium Rating Scale-Revised-98 (DRS-R98) scores were retrospectively calculated, when possible, at time antipsychotic was started to confirm the initial diagnosis of delirium and evaluate symptom severity, and again when antipsychotic was stopped, to assess symptom response. Results: Olanzapine (n=78), risperidone (n=13), and quetiapine (n=19) were used during the 2 years of the study. Mean patient age, length of treatment, and response were comparable for the three medications. For patients with two DRS-R98 scores available (n=75/110), mean DRS-R98 scores decreased significantly (p<0.001) with antipsychotic without significant adverse side effects. Conclusion: Although randomized placebo-controlled studies are needed, atypical antipsychotic medications appeared to be effective and safe for managing delirium symptoms in pediatric patients while underlying etiology was addressed.
机译:背景:非典型抗精神病药已被证明可有效治疗成年人的ir妄,但尽管有相当大的需求,但在儿科患者中对其使用的研究较少。目的:回顾性图表审查描述了非典型抗精神病药在控制儿童和青少年and妄症状中的作用。方法:回顾了洛杉矶儿童医院的药房记录,以确定在24个月内分配了抗精神病药的患者。回顾了同一24个月内的精神科住院咨询。被诊断为抗精神病药的ir妄的1-18岁患者构成了研究人群。可能时,在可能的时候,在开始使用抗精神病药确认confirm妄的初始诊断并评估症状严重程度时,以及在停止使用抗精神病药时再次评估again妄评估等级修订的98(DRS-R98)评分,以评估症状反应。结果:在研究的2年中使用了奥氮平(n = 78),利培酮(n = 13)和喹硫平(n = 19)。这三种药物的平均患者年龄,治疗时间和反应均相当。对于有两个可用DRS-R98评分(n = 75/110)的患者,平均DRS-R98评分显着降低(p <0.001),且抗精神病药没有明显的不良副作用。结论:尽管需要进行随机安慰剂对照研究,但非典型抗精神病药物似乎可有效且安全地治疗小儿患者的ir妄症状,同时还针对潜在病因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号